预约演示
更新于：2026-03-19
Tramadol Hydrochloride/Acetaminophen
氨酚曲马多
更新于：2026-03-19
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2001-08-15), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H35ClN2O4 |
InChIKeyUFLWHLMSTCRAJP-WUTOMRCLSA-N |
CAS号147630-10-2 |
关联
61
项与 氨酚曲马多 相关的临床试验CTRI/2024/11/076104
Comparison of fixed dose combination of Tramadol/Acetaminophen VS Codeine/Acetaminophen for management of mild-moderate pain in patients diagnosed with lung carcinoma - A Randomised Double Blinded Controlled Trial - NIL
NCT05406752
An Open-label, Single Treatment, Single Period, Single Buccal Dose Pharmacokinetic Study of Paracetamol Uniflash (125 mg/ 1.25 mL) in Healthy, Adult, Human Subjects Under Fasting Conditions.
CTRI/2021/12/038476
Comparison of pre-emptive paracetamol, paracetamol-diclofenac, paracetamol-tramadol combination for post-operative pain after lumbar spine surgery under general anaesthesia : A single blinded three arm randomized control study.
100 项与 氨酚曲马多 相关的临床结果
登录后查看更多信息
100 项与 氨酚曲马多 相关的转化医学
登录后查看更多信息
100 项与 氨酚曲马多 相关的专利（医药）
登录后查看更多信息
20
项与 氨酚曲马多 相关的文献（医药）2022-01-01Translational and clinical pharmacology
Comparative pharmacokinetics between two tablets of tramadol 37.5 mg/acetaminophen 325 mg and one tablet of tramadol 75 mg/acetaminophen 650 mg for extended-release fixed-dose combination
Article
作者: Lee, SeungHwan ; Kim, JaeWoo ; Kim, Hyun Chul ; Hong, Jang Hee ; Yoon, Deok Yong ; Jang, In-Jin
Trial Registration:
ClinicalTrials.gov Identifier: NCT01606059.
2021-01-01Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association4区 · 医学
Impact of background factors on outcomes of pharmacological therapy for chronic low back pain: A nationwide multicenter prospective study
4区 · 医学
Article
作者: Matsuyama, Yukihiro ; Yamashita, Toshihiko ; Haro, Hirotaka ; Mochida, Joji ; Inoue, Gen ; Yoshida, Munehito ; Kaito, Takashi ; Iwasaki, Motoki ; Taneichi, Hiroshi ; Shintani, Ayumi ; Takura, Tomoyuki ; Miyakoshi, Naohisa ; Yamazaki, Masashi ; Takahashi, Kazuhisa ; Murakami, Hideki ; Kawakami, Mamoru ; Kabata, Daijiro ; Ito, Manabu ; Taguchi, Toshihiko ; Ohtori, Seiji ; Yamada, Hiroshi ; Nishida, Kotaro ; Imagama, Shiro ; Yonenobu, Kazuo
BACKGROUND:
Chronic low back pain (CLBP) is a major cause of chronic pain with nociceptive, neuropathic or both pain components, and a leading cause of disability. The objectives of this study were to determine the impact of background factors including previous use of drugs on outcomes of pharmacological therapy for CLBP in a nationwide multicenter prospective study.
METHODS:
The subjects were 474 patients (male: 41.9%, median age: 73.0) with CLBP. Background factors that could influence outcomes after pharmacological treatment for 6 months were examined: age, gender, body mass index (BMI), duration of CLBP, osteoporosis, history of spinal surgery, history of malignant tumor, smoking habit, employment status (yes or no), exercise habit (frequency), number of live-in family members, having something to do for pleasure, Center for Epidemiologic Studies depression scale (CES-D) score, and medication at baseline. Japanese Orthopaedic Association (JOA) score, visual analogue scale (VAS) for LBP, JOA Back Pain Evaluation Questionnaire (JOABPEQ), Roland-Morris Disability Questionnaire (RDQ), Short-form 8-item health survey (SF-8), and EQ-5D were used for evaluation at baseline and after 6 months. Multivariate linear regression models were used in statistical analysis.
RESULTS:
Drugs for neuropathic pain at baseline (p < 0.001), Tramacet® at baseline (p < 0.05), weak opioids at baseline (p < 0.05), older age (p < 0.001), long disease duration (p < 0.005), history of spinal surgery (p < 0.001), and smoking habit (p < 0.001) had significant negative effects on outcomes. Employment (p < 0.05), exercise habit (p < 0.05), and CED-D at baseline (p < 0.001) had positive effects on outcomes.
CONCLUSIONS:
This is the first study to identify significant prognostic factors for outcomes of pharmacological treatment of CLBP. The neuropathic pain component of CLBP at baseline is a major significant negative factor for most outcomes involving improved pain, activities of daily life, and quality of life. Treatment strategies developed with consideration of these factors may be advantageous for recovery from CLBP.
2020-12-01Traditional & Kampo Medicine
An effective case of shichimotsukokato treatment for postherpetic neuralgia in a patient with chronic kidney disease
作者: Fujii, Tomoaki ; Morimoto, Yuji
ABSTRACT:
Case:
A 78‐year‐old female who had chronic kidney disease developed postherpetic neuralgia. She was prescribed several analgesics, but the pain was severe.
Outcome:
Shichimotsukokato was prescribed to this patient, and her pain was gradually relieved. During the course of treatment, the pain worsened when tramadol hydrochloride acetaminophen tablets were interrupted and improved upon their resuming their administration, suggesting an effect for the combination with shichimotsukokato. Her renal function did not worsen, but rather seemed to have improved.
Conclusion:
Analgesics can be inappropriately used in patients with chronic kidney disease. For chronic kidney disease patients with postherpetic neuralgia, shichimotsukokato may have an effect on both pain and renal function and seems to be beneficial.
100 项与 氨酚曲马多 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 疼痛 | 澳大利亚 | 2012-03-19 | |
| 癌症疼痛 | 日本 | 2011-04-22 | |
| 急性疼痛 | 美国 | 2001-08-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 腰痛 | 临床3期 | - | 2009-05-01 | |
| 慢性疼痛 | 临床3期 | 日本 | 2008-05-01 | |
| 术后疼痛 | 临床3期 | 日本 | 2008-03-01 | |
| 踝损伤 | 临床3期 | - | 2003-12-01 | |
| 肌肉骨骼疼痛 | 临床3期 | - | 2003-12-01 | |
| 扭伤和拉伤 | 临床3期 | - | 2003-12-01 | |
| 膝关节炎 | 临床2期 | - | 2007-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 32 | 鹹繭齋繭襯製選積築鹹(鹽顧窪築淵積餘鬱簾憲) = 簾觸艱獵淵蓋製構鏇觸 積鬱鏇壓獵憲齋窪積鹹 (獵憲夢鑰醖願餘憲鑰範, 1148.85) 更多 | - | 2024-12-13 | |||
N/A | 48 | 顧糧餘蓋鹽膚鑰選範選(獵醖糧蓋艱製膚鏇淵觸) = 築窪憲鏇餘構壓淵繭餘 觸艱簾齋鬱憲鹽顧選網 (憲獵築鹽構繭範範築襯 ) 更多 | 积极 | 2018-07-27 | |||
NSAID (Naproxen 500mg) | 顧糧餘蓋鹽膚鑰選範選(獵醖糧蓋艱製膚鏇淵觸) = 願願繭廠糧艱窪糧觸繭 觸艱簾齋鬱憲鹽顧選網 (憲獵築鹽構繭範範築襯 ) 更多 | ||||||
临床4期 | 51 | (Group Z) | 獵鹹衊鏇鏇範觸簾襯醖(廠遞觸繭構鏇艱簾繭夢) = 網艱膚鹹壓顧膚網鬱構 簾艱鑰糧醖繭夢鹹鏇夢 (淵蓋選築壓構蓋鹽壓構, 1.28) 更多 | - | 2015-08-13 | ||
(Group PT) | 獵鹹衊鏇鏇範觸簾襯醖(廠遞觸繭構鏇艱簾繭夢) = 遞膚遞繭膚鏇獵襯艱廠 簾艱鑰糧醖繭夢鹹鏇夢 (淵蓋選築壓構蓋鹽壓構, 1.86) 更多 | ||||||
临床4期 | 200 | 遞鏇壓範鏇範餘鏇範鑰 = 繭繭壓鹽膚艱淵繭鹹顧 襯製製糧膚廠淵鏇遞淵 (蓋餘遞網鬱積蓋襯憲齋, 淵鹹衊鏇鹽壓餘簾鑰鹽 ~ 淵築繭積獵鹽鹹餘築窪) 更多 | - | 2014-06-09 | |||
临床3期 | 321 | Placebo (Double-Blind) | 鏇鹽艱積鹹鑰醖積範製 = 壓糧積鑰鹽鹽觸獵獵願 憲窪觸製製鹹鬱蓋糧廠 (鹹構醖廠夢顧壓繭醖醖, 製鑰獵願繭廠鹽憲範積 ~ 餘網艱壓齋製衊範齋衊) 更多 | - | 2013-09-26 | ||
临床4期 | 1,059 | 壓夢鹹繭齋衊憲鬱衊淵(鬱淵廠製餘艱獵壓製築) = 選窪壓願壓顧鹹鹽鏇遞 鹹窪網繭襯醖鏇襯鏇積 (糧醖衊網醖糧艱壓繭鏇, 2.07) 更多 | - | 2013-08-26 | |||
临床3期 | 328 | Placebo+Acetaminophen | 衊憲範齋糧齋構築壓鹽(製製鏇醖憲積製餘遞繭) = 積獵餘構積簾窪襯襯糧 選衊築餘繭鹹壓壓顧衊 (蓋鹽夢窪觸鏇鏇淵壓蓋, 8.07) 更多 | - | 2013-08-01 | ||
临床3期 | 248 | Placebo | 構選觸鏇糧積製齋製廠 = 壓鏇衊鏇膚襯夢顧餘憲 築糧鏇餘艱齋鹽築窪顧 (齋淵壓獵廠壓憲齋鹽廠, 顧壓壓廠窪廠廠遞鏇鹽 ~ 範遞襯壓糧襯壓憲築遞) 更多 | - | 2013-07-24 | ||
临床4期 | 162 | 構獵簾壓鹽網積夢壓鑰(鏇顧壓壓淵壓鹹構壓鬱) = 構夢膚網醖齋糧淵齋網 齋淵鹹鬱衊願齋獵繭淵 (願膚夢蓋憲網醖憲網鬱, 1.58) 更多 | - | 2013-07-16 | |||
临床4期 | 143 | 鏇壓積鬱築衊膚鹽遞衊(鹽餘積鹽餘衊鹽獵襯獵) = 鬱窪壓鬱糧顧觸淵廠淵 窪艱範艱選壓鑰顧製積 (鹽獵遞餘範繭獵製製糧, 14.17) 更多 | - | 2013-06-24 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用